Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASH 2022 Lymphoma & CLL Highlights

19 January 2023 | Virtual Meeting

Post-ASH 2022 Lymphoma & CLL Highlights

19 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in lymphoma and chronic lymphocytic leukemia (CLL) from ASH 2022

The Post-ASH 2022 Lymphoma & CLL Virtual Workshop took place on 19 January 2022, and featured a series of short presentations from invited experts on selected abstracts from the 64th ASH Annual Meeting with interactive panel discussions after each session.

Addressing unmet needs in lymphoma Mantle cell lymphoma Advances in CLL, SLL and Richter's transformation Key updates for CAR-T in lymphoma Treatment updates for DLBCL
Session 1: addressing unmet needs in lymphoma 
Lorenzo Falchi
Phase I/II study of subcutaneous epcoritamab with R2 in 1L FL
Lorenzo Falchi Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Yago Nieto
AFM13 plus cord blood-derived NK cells in double-refractory CD30+ lymphoma
Yago Nieto The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Catherine Thieblemont
Iberdomide alone or with anti-CD20 antibody in R/R lymphoma
Catherine Thieblemont Saint-Louis Hospital, Paris, France
Session 1 panel discussion
Session 2: mantle cell lymphoma
Bijal Shah
Phase II study of ALR with real-time monitoring of MRD in 1L MCL
Bijal Shah H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Adrian Minson
Tarmac study: time-limited ibrutinib and tisa-cel in R/R MCL
Adrian Minson Peter MacCallum Cancer Centre, Melbourne, Australia
Nirav Niranjan Shah
Tandem study: bispecific LV20.19 CAR-Ts for MCL
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
Session 2 panel discussion
Session 3: advances in CLL, SLL and Richter’s transformation
Jennifer Brown
ALPINE study: zanubrutinib vs ibrutinib for R/R CLL/SLL
Jennifer Brown Dana-Farber Cancer Institute, Boston, MA, United States
Talha Munir
FLAIR study: ibrutinib + venetoclax with MRD-driven treatment duration in CLL
Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Nirav Niranjan Shah
BRUIN study: pirtobrutinib in Richter's transformation
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
Arnon Kater
EPCORE CLL-1 study: subcutaneous epcoritamab in Richter's syndrome
Arnon Kater University of Amsterdam, Amsterdam, Netherlands
Session 3 panel discussion
Session 4: key updates for CAR-T in lymphoma
Joanna Zurko
Survival outcomes with CD19 CAR-T therapy in DHL and DEL
Joanna Zurko Medical College of Wisconsin, Milwaukee, WI, United States
Caron Jacobson
Targeting CNS lymphoma with intravenous axi-cel
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Roch Houot
Alycante study: axi-cel as 2L therapy in transplant-ineligible lymphoma
Roch Houot Rennes University Hospital, Rennes, France
Caron Jacobson
Pilot study of axi-cel for R/R primary and secondary CNS lymphoma
Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States
Manali Kamdar
Transform study: liso-cel vs SOC in 2L for R/R LBCL
Manali Kamdar University of Colorado Cancer Center, Denver, CO, United States
Session 4 panel discussion
Session 5: treatment updates for DLBCL
Pere Barba
Phase I study of rapcabtagene autoleucel in R/R LBCL
Pere Barba Vall d’Hebron University Hospital, Barcelona, Spain
Won-Seog Kim
ELM-2 study: odronextamab in R/R DLBCL
Won-Seog Kim Samsung Medical Center, Seoul, Korea, Republic of
Session 5 panel discussion

Supporters:

Platinum

Gold

Silver

The continued success of the post-ASH meetings is in no small part due to the ongoing funding of supporters, allowing unique opportunities for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future meetings and activities, please contact us here.

For the latest updates in Lymphoma and CLL, visit The Lymphoma Channel and The CLL Channel

The content of VJHemOnc is intended for healthcare professionals